(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
The study hypothesis is that patients with clinical stage II-III TNBC with more than 1 cm of residual disease and basal-like subtype in their surgical specimen after neoadjuvant chemotherapy that are treated with adjuvant platinum based chemotherapy will have a longer invasive disease-free survival (IDFS) than the ones capecitabine arm.
Study Number: 

NCG 275315

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.